The present invention relates to a method and a composition to prevent or treat acne by selective inhibition of P. acnes bacteria. This is delivered using a composition comprising P. acnes phage-derived endolysins where the actives are maintained at conditions like use of non-ionic polymers and specific pH and electrolytes range that ensure maximal inhibition efficacy.

The present invention relates to new species-selective phage endolysins and their use to treat bacterial vaginosis (BV). The present invention provides recombinant endolysins, i.e. domain-swapped endolysins. The invention also relates to said endolysins for use in treating diseases or disorders such as bacterial infections, in particular BV. The invention further relates to polynucleotides encoding said endolysins. Said polynucleotides can also be used for treating such diseases or disorders. Also provided by the present invention is a pharmaceutical composition comprising an endolysin of the invention for use in treating such diseases or disorders. Said endolysins, polynucleotides and pharmaceutical composition may be administered locally, in particular locally into the vagina.

The present disclosure features compositions and methods for the treatment of bacterial infections, such as bacterial infections caused by bacterial cells residing within a host cell (e.g., a mammalian cell, e.g., immune cell, e.g., macrophage or dendritic cell). The compositions and methods include delivering a bacteriophage and an antibacterial lytic protein to the intracellular computment (endosome, phagosome, lysosome, or cytosol) in which the bacterial cell resides.

Compositions comprising doses of NSAIDs less than 75 mg are provided. As shown herein, these compositions may be used for the treatment and prophylaxis of inflammatory conditions on the mucosa. In particular, acetyl salicylic acid at doses of less than 75 mg is shown to have therapeutic and prophylactic effect on the mucosa coupled without the adverse effects associated with NSAID administration.

Provided is a protein derived from Tumebacillus sp. NITE BP-02779 and having peptidoglycan-degrading activity. Provided is a protein comprising the amino acid sequence at positions 1 to 164 of SEQ ID NO: 2 or the amino acid sequence at positions 1 to 493 of SEQ ID NO: 4, or the amino acid sequences with a substitution, deletion, insertion, or addition of 1 to 10 amino acid residues, or an amino acid sequence having 90% or more identity to the amino acid sequences, and having peptidoglycan-degrading activity.

Methods of making engineered protein-based materials, nanofibers, and biofilms from bacterial amyloid-based structures that are capable of mediating long-range electron transport are provided.

The disclosure discloses a genetically engineered strain for producing porcine myoglobin and fermentation and purification thereof, and belongs to the technical field of genetic engineering. The disclosure realizes efficient secretion and expression of porcine myoglobin by integrating the gene of porcine myoglobin in P. pastoris. On this basis, optimization of the medium and culture conditions of recombinant P. pastoris can significantly increase the titer of porcine myoglobin, so that the titer can reach 285.42 mg/L under fermenter conditions. In addition, by creatively adding different concentrations of ammonium sulfate to fermentation broth step by step, the purity of myoglobin obtained by final concentration is up to 88.0%, and the purification rate is up to 66.1%. The disclosure realizes efficient expression and high purification of porcine myoglobin from various steps such as synthesis, fermentation and purification of porcine myoglobin, and provides broad prospects for industrial production of porcine myoglobin.

The present technology relates generally to formulations comprising egg white protein, methods of manufacturing egg protein formulations and uses for egg protein formulations. In particular, several embodiments are directed to egg protein formulations for oral administration in immunotherapy of subjects affected by egg allergies.

The present invention relates to the field of medicine, specifically to the field of treatment of a malignant condition associated with infection with a bacterium that aggravates and/or induces proliferation of the malignant conditions.

New recombinant lysin and its use in the treatment of gram-negative bacterial infections The present invention relates to a new recombinant lysin and its use as antimicrobial agent in new treatment approaches for eliminating antibiotic resistant Gram-negative bacteria, and minimizing the emergence of new resistances. It further concerns polynucleotides encoding the recombinant lysin of the invention, vectors and host cells comprising the same, as well as related methods, medical uses, compositions and kits.